Tuesday , January 26 2021

Heberprot-P: The challenge of prevention is still standing

HAVANA.- Registration in nearly 30 countries of all latitudes and a group of 290,000 patients treated after their release a decade ago are some of the achievements of Heberprot-P, the only remedy in the world to treat ulcers in the world. diabetic foot,

In fact, the disease, considered a global pandemic, has a high incidence on the island, with figures targeting the millions who suffer from it.

However, drug-related studies and pharmacovigilance studies do not stop. Her developers, from Center for Genetic Engineering and Biotechnology (CIGB) are now seeking that the injected drug, the active ingredient of which is an epidermal growth factor, is less invasive to the patient.

Applied directly to ulcerative tissues, he infiltrates lesions with a needle at a depth of 0.1 centimeter.

Such a procedure is sometimes painful for the patient, especially at the borders and bottom of the lesions during the application, said Cuban scientist Jorge Berlinga, the research leader.

The group of formulations of CIGB works in the search for a new pharmaceutical form, the so-called intelligent formulations that are characterized by a continuous release property in time.

The goal is to reduce the number of treatments, with this hypothesis that we are working on.

"Thus, if some of the alternatives were achieved, it would be a step forward, but a great challenge, and we must see how the cage responds to long-lasting liberation, as the successor changes, this is a challenge for us," Berlanga explains.

But the availability of a unique drug available to patients to treat this medical problem is not a solution. Scientists say preventive work is needed, especially in a country whose predictions show that by the middle of the century adults over 60 are one third of the population.

In addition to being a social problem, from an economic point of view, it is necessary to stop the progression of the primary care disease, as according to the specialists, many of the injuries manage to be treated and closed down in the early stages where there is little complexity.

This reduces direct and indirect costs within health systems. This helps the family economy as well as the economy of the country, they explain.

At the same time, the Cuban anthology community has been focusing on better epidemiological strategies to cope at least with the possible diseases that have yet to come, said Alejandro Hernández, director of the Institute of Angiology and Vascular Surgery. the goal of AngioCaribe 2016.

Developing preventive programs at primary care level to avoid difficult situations in patients is one of the premises, he said.

At that time, the plant presented the study "The magnitude and transcendence of peripheral vascular diseases in Cuba to uncover the spread of these diseases on the island."

Its results suggest that peripheral vascular disease occurs Cuba among the 10 leading causes of death (seventh), with a gross mortality rate of 25.5 per 100,000 inhabitants, therefore the need to achieve coherent intervention strategies, as stated in the statistics, in the world, in the case of peripheral arterial two thirds of the people who suffer from them are asymptomatic and not diagnosed.

Under these circumstances, the above-mentioned scientific institutions are organizing the International Congress for the Control of Diabetes and its Worst Complications – an assignment that brings together researchers from all latitudes and a great representation of the United States.

In fact, the American nation is interested in having this drug. At the beginning of the year, Cuban company Heber Biotec, CIGB, and American company Mercurio Biotec agreed to join forces to bring Heberprot-P therapy to patients with diabetic foot ulcer in the northern nation after being approved by the Drug and Food Administration from this country (FDA, for acronym in English).

Scientists from the United States and colleagues from other parts of the world will be able to learn about the latest achievements in the treatment of this disease in five symposia among them. Endocrinology of diabetes, state of the art in the treatment of wound healing, and the implementation of comprehensive health care programs for people with diabetes.

They give cardiovascular problems related to diabetes, and implement health care programs for the overall care of people with diabetes.

Source link